Rybelsus, the first oral GLP-1 receptor agonist approved for diabetes, has become a focal point in discussions about effective dosing strategies. Its unique formulation allows it to be taken orally, yet successful management of blood sugar levels depends heavily on proper dose discipline. Patients often face challenges in adhering to…